Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Completed · Phase 4

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.

Key facts

Study ID

NCT00106821

Run by

Boehringer Ingelheim

People needed

166

Starts

2004-06-01

Last updated by the study team

2013-11-01

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female of African descent
• 40 years of age or older
• Diagnosis of COPD
• History of smoking at least one pack per day for at least 10 years
• Currently experiencing shortness of breath at least with exertion

You may not qualify if…

• Asthma
• Recent myocardial infarction or hospitalization for congestive heart failure

Where it is running

• Boehringer Ingelheim Investigational Site — Birmingham, Alabama, United States
• Cooper Green Hospital — Birmingham, Alabama, United States
• University of Alabama at Birmingham — Birmingham, Alabama, United States
• David Geffen School of Medicine — Los Angeles, California, United States
• VA Greater Los angeles Health Care Systems — Sepulveda, California, United States
• Boehringer Ingelheim Investigational Site — Waterbury, Connecticut, United States
• Yale Univ. Pulmonary and Critical Care Medicine — West Haven, Connecticut, United States
• Emerald Coast Research Associates — Panama City, Florida, United States
• Bay Pines V. A. Medical Center — Saint Petersberg, Florida, United States
• Louisiana State University School of Medicine — New Orleans, Louisiana, United States
• LSU MC-Sheveport — Shreveport, Louisiana, United States
• Bronx VA Medical Center — The Bronx, New York, United States
• Brody School of Medicine, East Carolina University — Greenville, North Carolina, United States
• Boehringer Ingelheim Investigational Site — Philadelphia, Pennsylvania, United States
• Temple University Hospital — Philadelphia, Pennsylvania, United States
• Boehringer Ingelheim Investigational Site — Charleston, South Carolina, United States
• Spartanburg Medical Research — Spartanburg, South Carolina, United States
• Attention: Amir Sharafkhaneh, M.D. — Houston, Texas, United States
• VAMC Houston — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.